CK-0801

N/A

Report date: 2026/04/28 20:00:22

Base Information

Drug NameCK-0801
Drug Alias NameCK-0801
ClassificationCell and gene therapy > Cell therapy > Donor > AllogeneicCell and gene therapy > Cell therapy > Source of cells > Umbilical cord blood-derivedCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Tregs
Mechanisms of ActionT lymphocyte replacementsImmunologic cytotoxicity
TargetsNot applicable
Therapy Area/IndicationsBone Marrow DiseasesAnemia, AplasticGuillain-Barre Syndrome
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesCellenkos IncThe University Of Texas MD Anderson Cancer Center
China Registration ClassN/A

Develop Information

Active CompaniesCellenkos Inc
Inactive CompaniesN/A
Active IndicationsBone Marrow DiseasesAnemia, Aplastic
Inactive IndicationsGuillain-Barre Syndrome

Other Information

ATC CodeN/A
Related LinksN/A